Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 20:12:727201.
doi: 10.3389/fgene.2021.727201. eCollection 2021.

Gene Targets Network Analysis for the Revealing and Guidance of Molecular Driving Mechanism of Lung Cancer

Risheng Huang  1 , Xiao Xiang  2 , Kangliang Zhang  3 , Yuanliang Zheng  1 , Chichao Wang  1 , Guanqiong Hu  4
Affiliations

Gene Targets Network Analysis for the Revealing and Guidance of Molecular Driving Mechanism of Lung Cancer

Risheng Huang et al. Front Genet. .

Abstract

The objective was to explore the function of gene differential expressions between lung cancer tissues and the interaction between the relevant encoded proteins, thereby analyzing the important genes closely related to lung cancer. A total of 120 samples from the GEO database (including two groups, i.e., 60 lung cancer in situ specimens and 60 normal specimens) were taken as the research objects, which were submitted to the analysis of signaling pathway, biological function enrichment, and protein interactions to reveal the molecular driving mechanism of lung cancer. Results: A total of 875 differentially expressed genes were obtained, including 291 up-regulated genes and 584 down-regulated genes. The up-regulated genes were mainly involved in biological processes such as protein metabolism, protein hydrolysis, mitosis, and cell division. Down-regulated genes were mainly involved in neutrophil chemotaxis, inflammatory response, immune response, and angiogenesis. The protein expression of high expression genes and low expression genes in patients were higher than those in the control group. The protein corresponding to the high expression gene was highly expressed in the patient group. Meanwhile, the proteins corresponding to the low expression genes were also expressed in the patient group, which showed that although the proteins corresponding to the low expression genes were low in the patients, they were still the target genes related to lung cancer. In conclusion, the molecular driving mechanism in lung cancer was mainly related to protein metabolism, proteolysis, mitosis, and cell division. It was found that TOP2A, CCNB1, CCNA2, CDK1, and TTK might be the critical target genes of lung cancer.

Keywords: gene target network analysis; lung cancer; molecular driving mechanism; nursing guidance; protein interaction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Influences of patients’ clinical characteristics on their quality of life (1: Stage I-II; 2: Stage III-IV; 3: Chemotherapy less than 3 times; 4: Chemotherapy more than 3 times).
FIGURE 2
FIGURE 2
The log2FC values of first 10 up-regulated genes and first 10 down-regulated genes that had relatively large differences (A) the first 10 up-regulated genes; (B) the first 10 down-regulated genes.
FIGURE 3
FIGURE 3
COL11A1 upstream and downstream network signal transduction in different tissues (1 and 3: normal human tissue; 2 and 4: lung cancer tissue).
FIGURE 4
FIGURE 4
Metastatic molecular types of COL11A1 in different tissues (1 and 3: normal human tissue; 2 and 4: lung cancer tissue).
FIGURE 5
FIGURE 5
The GO analysis results (A) the first 10 up-regulated genes; (B) the first 10 down-regulated genes.
FIGURE 6
FIGURE 6
The KEGG pathway analysis results (A) showed the differently expressed up-regulated genes; (B) showed the differently expressed down-regulated genes.
FIGURE 7
FIGURE 7
Significant modules in the protein-protein interaction network (A) showed the highly expressed genes; (B) showed the low expressed genes.
FIGURE 8
FIGURE 8
Protein expressions of CCNB1 and TOP2A in lung cancer patients.
FIGURE 9
FIGURE 9
The expression of messenger RNA corresponding to CCNB1 and TOP2A proteins in the control and experimental groups (1: CCNB1; 2: TOP2A).
FIGURE 10
FIGURE 10
Protein expressions of IL6 and IL1B in patients with lung cancer.
FIGURE 11
FIGURE 11
The messenger RNA expressions of IL6 and IL1B proteins in the control and experimental groups (1: IL6; 2: IL1B).
See this image and copyright information in PMC

References

    1. Allan-Blitz L. T., Hemarajata P., Humphries R. M., Wynn A., Segura E. R., Klausner J. D. A. (2018). Cost analysis of gyrase a testing and targeted ciprofloxacin therapy versus recommended 2-drug therapy for Neisseria gonorrhoeae infection. Sex. Transm. Dis. 45 87–91. 10.1097/olq.0000000000000698 - DOI - PMC - PubMed
    1. Horimasu Y., Ishikawa N., Taniwaki M., Yamaguchi K., Hamai K., Iwamoto H., et al. (2017). Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Med. Genet. 18:88. 10.1186/s12881-017-0449-9 - DOI - PMC - PubMed
    1. Krasnov G. S., Puzanov G. A., Kudryavtseva A. V., Dmitriev A. A., Beniaminov A. D., Kondratieva T. T., et al. (2017). Differential expression of an ensemble of the key genes involved in cell-cycle regulation in lung cancer. Mol. Biol. 51 740–747. 10.1134/s0026893317050107 - DOI - PubMed
    1. Masters G. A., Johnson D. H., Temin S. (2017). Systemic therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J. Oncol. Pract. 33 832–837. 10.1200/jop.2017.026716 - DOI - PubMed
    1. Shen J., Hu Y., Putt K. S., Singhal S., Han H., Visscher D. W., et al. (2018). Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget 9 4485–4495. 10.18632/oncotarget.23321 - DOI - PMC - PubMed